InterCure Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
285
- Stock Symbol
-
INCR
- Investments
-
11
- Share Price
-
$3.28
- (As of Friday Closing)
InterCure General Information
Description
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Contact Information
Website
www.canndoc.comCorporate Office
- Number 85 Medinat Hayehudim
- Herzliya
- Israel
Corporate Office
- Number 85 Medinat Hayehudim
- Herzliya
- Israel
InterCure Stock Performance
As of 20-Nov-2026, InterCure’s stock price is $3.28. Its current market cap is $42M with 13M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.28 | $3.49 | $3.12 - $7.55 | $42M | 13M | 25.5K | -$0.95 |
InterCure Financials Summary
As of 31-Dec-2025, InterCure has a trailing 12-month revenue of $77.8M.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 87,840 | 87,840 | 107,853 | 80,132 |
| Revenue | 77,767 | 77,767 | 64,050 | 95,967 |
| EBITDA | (2,547) | (2,547) | (14,483) | (7,902) |
| Net Income | (10,278) | (10,278) | (18,180) | (16,723) |
| Total Assets | 217,295 | 217,295 | 208,763 | 207,205 |
| Total Debt | 57,588 | 57,588 | 57,874 | 51,544 |
InterCure Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
InterCure Comparisons
Industry
Financing
Details
InterCure Competitors (2)
One of InterCure’s 2 competitors is IM Cannabis, a Formerly PE-Backed company based in Kibbutz Glil Yam, Israel.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IM Cannabis | Formerly PE-Backed | Kibbutz Glil Yam, Israel | ||||
| Bedrocan International | Corporate Backed or Acquired | Veendam, Netherlands |
InterCure Patents
InterCure Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2009090646-A2 | Determination of physiological parameters using repeated blood pressure measurements | Inactive | 15-Jan-2008 | ||
| AU-2005264165-A1 | Apparatus and method for breathing pattern determination using a non-contact microphone | Inactive | 23-Jul-2004 | ||
| CA-2574642-A1 | Apparatus and method for breathing pattern determination using a non-contact microphone | Inactive | 23-Jul-2004 | ||
| EP-1804649-A2 | Apparatus and method for breathing pattern determination using a non-contact microphone | Inactive | 23-Jul-2004 | ||
| EP-1804649-A4 | Apparatus and method for breathing pattern determination using a non-contact microphone | Inactive | 23-Jul-2004 | A61B5/08 |
InterCure Signals
InterCure Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
InterCure Investments & Acquisitions (11)
InterCure’s most recent deal was a Merger/Acquisition with Botanico. The deal was made on 15-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Botanico | 15-Jun-2026 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Cannasoul Analytics | 03-Nov-2025 | Later Stage VC | Drug Discovery | ||
| Leon Pharm | 01-Jun-2024 | Merger/Acquisition | Pharmaceuticals | ||
| Cannomed (2 Medical Cannabis Dispensing Pharmacies and Patient Support Center) | 02-Sep-2021 | Corporate Asset Purchase | Therapeutic Devices | ||
| Pharmazone (Raanana) | 18-May-2021 | Merger/Acquisition | Distributors (Healthcare) |
InterCure ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
InterCure Exits (1)
InterCure’s most recent exit was on 17-Feb-2015 from Regenera Pharma. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Regenera Pharma | 17-Feb-2015 | Completed |
|
InterCure Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Leon Pharm | Tel Aviv, Israel | 1988 |
InterCure FAQs
-
When was InterCure founded?
InterCure was founded in 1994.
-
Where is InterCure headquartered?
InterCure is headquartered in Herzliya, Israel.
-
What is the size of InterCure?
InterCure has 285 total employees.
-
What industry is InterCure in?
InterCure’s primary industry is Pharmaceuticals.
-
Is InterCure a private or public company?
InterCure is a Public company.
-
What is InterCure’s stock symbol?
The ticker symbol for InterCure is INCR.
-
What is the current stock price of InterCure?
As of 20-Nov-2026 the stock price of InterCure is $3.28.
-
What is the current market cap of InterCure?
The current market capitalization of InterCure is $42M.
-
What is InterCure’s current revenue?
The trailing twelve month revenue for InterCure is $77.8M.
-
Who are InterCure’s competitors?
IM Cannabis and Bedrocan International are competitors of InterCure.
-
What is InterCure’s annual earnings per share (EPS)?
InterCure’s EPS for 12 months was -$0.95.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process